DOR 8K Delist Notice and new Symbol Notice
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): April
18, 2006
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1691
Michigan Ave., Suite 435
Miami,
FL
|
|
33139
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item 3.01.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer
of Listing.
Dor
BioPharma, Inc. (the “Company”) did not maintain a shareholder equity balance of
at least $6 million in accordance with Section 1003(a)(iii) of the AMEX Company
Guide. Accordingly, on April 18, 2006, the Company’s common stock was delisted
from AMEX and began trading on the Over-the-Counter Bulletin Board under the
ticker symbol “DORB.”
Item
9.01. Financial
Statements and Exhibits.
(c) Exhibits.
99.1 Press
Release issued by the Company dated April 18, 2006.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By:
/s/
Michael T.
Sember
Name:
Michael T. Sember
Title:
President and Chief Executive Officer
Date:
April 20, 2006
EXHIBIT
INDEX
99.1 Press
Release issued by the Company dated April 18, 2006.